2022
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar S, Shum E, Grello C, Lau S, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers In Oncology 2022, 12: 877594. PMID: 35992832, PMCID: PMC9382405, DOI: 10.3389/fonc.2022.877594.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint blockadeProgression-free survivalCell lung cancerLung cancerAnti-cytotoxic T-lymphocyte-associated protein 4 antibodyAnti-programmed death-1 antibodyDeath-1 antibodyFuture of immunotherapyOverall survival benefitProtein 4 antibodyViable therapeutic approachIdentification of biomarkersFree survivalCheckpoint blockadeDurable responsesSurvival benefitModulating therapiesCombination therapyClinical trialsTherapeutic approachesImmunotherapyFuture careLigand antibodyCellular therapy
2020
Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.
Cytryn S, Punekar S, Tenet M, Ullah T, Wang B, Goldberg J, Velcheti V, Wong K, Chachoua A, Shum E, Sabari J. Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib. Journal Of Clinical Oncology 2020, 38: e21679-e21679. DOI: 10.1200/jco.2020.38.15_suppl.e21679.Peer-Reviewed Original ResearchNon-small cell lung cancerGeneration TKIsAdvanced diseaseSuperior PFSDe novo stage IV diseaseMutant non-small cell lung cancerEGFR-mutant non-small cell lung cancerLines of therapySecond-line therapyStage IV diseaseKaplan-Meier curvesCell lung cancerGeneration EGFR-TKINon-Asian patientsT790M resistanceInstitution's IRBMedian PFSBrain metastasesComparison of subgroupsFree survivalLine therapyBaseline characteristicsEGFR therapyEGFR-TKIRetrospective study